Trial design-OV67

NSGO-CTU/UPLIFT

Clinical Trial Study: OV67

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In
Patients with Solid Tumors Likely to Express NaPi2b.

Study design